Bridgefront Capital’s Charles River Laboratories CRL Stock Holding History

Bridgefront Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,355	Closed	-$368K	–	575
2025 Q3	$368K	Buy	+2,355	New	+$374K	0.11%	336
2025 Q1	–	Sell	-5,845	Closed	-$1.08M	–	667
2024 Q4	$1.08M	Buy	5,845 +2,014	+53%	+$388K	0.36%	59
2024 Q3	$755K	Buy	3,831 +1,169	+44%	+$243K	0.29%	91
2024 Q2	$550K	Buy	+2,662	New	+$603K	0.23%	147
2023 Q4	–	Sell	-2,023	Closed	-$396K	–	409
2023 Q3	$396K	Buy	+2,023	New	+$415K	0.28%	123
2023 Q2	–	Sell	-1,826	Closed	-$369K	–	494
2023 Q1	$369K	Buy	+1,826	New	+$414K	0.22%	164
2022 Q3	–	Sell	-1,136	Closed	-$243K	–	338
2022 Q2	$243K	Buy	+1,136	New	+$278K	0.27%	178

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Bridgefront Capital's CRL Position: Q4 2025 in Review

Bridgefront Capital sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 2,355 shares — an estimated $368K sold.

Bridgefront Capital first reported a position in CRL in Q2 2022 and held it in 7 quarters. The position peaked at $1.08M in Q4 2024. 583 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

Bridgefront Capital reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
Bridgefront Capital sold 2,355 Charles River Laboratories shares in Q4 2025, an estimated $368K.
Bridgefront Capital first reported a position in Charles River Laboratories in Q2 2022 and held it in 7 quarters.
Bridgefront Capital's Charles River Laboratories position peaked at $1.08M in Q4 2024.
583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.